For laboratory research education only. Not for human or animal use or consumption.

GHK-Cu and AHK-Cu are copper-associated tripeptides whose peptide sequences differ at the first amino-acid residue. GHK contains glycine–histidine–lysine; AHK contains alanine–histidine–lysine. That difference makes them distinct chemical entities, even though both names appear in discussions of copper-peptide research. [1] [2]

A useful comparison starts with molecular identity, the material actually examined, and the experimental question. A finding about one peptide cannot automatically be assigned to the other. Similarly, a laboratory observation does not establish that a commercial material is suitable for personal use.

What do the names mean?

The letters G, A, H, and K are one-letter amino-acid codes. G represents glycine, A represents alanine, H represents histidine, and K represents lysine. “Cu” identifies copper in the reported complex. The studies discussed here concern copper(II), also written Cu²⁺. For background on peptide terminology, see What Are Peptides?

Feature	GHK-Cu	AHK-Cu
Peptide sequence	Gly–His–Lys	Ala–His–Lys
First residue	Glycine	Alanine
Shared residues	Histidine and lysine	Histidine and lysine
Selected evidence discussed here	Copper-binding thermodynamics, structural characterization, crystallography, and sensor research	A laboratory study using cultured cells and isolated tissue
Interpretation	Evidence applies to the tested chemical form and experimental system	Evidence applies to the tested chemical form and experimental system

GHK without copper and a GHK–copper complex are not interchangeable descriptions. Likewise, AHK and AHK-Cu should be distinguished in study records. A short product name alone does not specify the complete analytical composition of a sample.

Why copper-binding conditions matter

Copper coordination describes how copper interacts with chemical groups on a peptide. In a structural investigation of GHK and DAHK complexes, researchers used X-ray and spectroscopic methods to examine copper coordination in solid samples and in solution. The GHK complex did not have identical organization in both settings. This illustrates why a single molecular illustration cannot describe every experimental state. [3]

A separate thermodynamic study used isothermal titration calorimetry to examine copper binding to GHK and DAHK. The authors accounted for competing ligands and buffer effects when reporting conditional binding parameters. Such results must be interpreted with their measurement conditions. DAHK is a four-residue peptide, Asp–Ala–His–Lys; it is not AHK. These studies therefore should not be presented as direct GHK-Cu-versus-AHK-Cu comparisons. [2]

What kinds of GHK research have been published?

GHK-related research extends beyond biological assays. In a 2020 study, scientists incorporated a GHK sequence into engineered proteins and investigated its use in copper-assisted crystallization and structure determination. The findings concerned those engineered constructs, rather than a general property validated for every standalone GHK-Cu preparation. [4]

In 2023, another group attached GHK to artificial nanochannels to investigate copper-ion detection. Copper binding changed the device’s electrical behavior. This was an analytical sensing system, not a test of human outcomes. [5]

These examples show why the phrase “GHK research” needs context: a free peptide, a copper complex, a protein tag, and a surface-bound sensor component are different experimental materials. For a separate introduction, see What Is GHK-Cu?

What does the cited AHK-Cu study establish?

Pyo and colleagues published a study in 2007 examining AHK-Cu in cultured dermal papilla cells and isolated human hair follicles maintained outside the body. The investigators measured cell and tissue endpoints under controlled laboratory conditions. This was not a clinical trial in people and did not compare AHK-Cu directly with GHK-Cu. [1]

Its experimental findings do not establish the safety or effectiveness of commercial AHK-Cu materials for personal use. Nor do they justify describing AHK-Cu as a superior version of GHK-Cu. A direct comparison would require both materials to be characterized and evaluated within an appropriately controlled, comparable system.

How should researchers compare analytical documentation?

A meaningful material comparison should distinguish identity, purity, content, and copper characterization. These answer different questions. Analytical validation guidance emphasizes that a method must be suitable for its intended purpose; when one procedure cannot provide adequate discrimination, complementary methods may be needed. The pharmaceutical guidance cited here supplies general analytical principles, not an RUO certification pathway. [6]

• Identity: What evidence supports the reported peptide sequence and chemical form?
• Purity: Which impurities can the method separate and detect, and how is the reported percentage calculated?
• Content: Was the amount of peptide independently measured, rather than inferred from a purity percentage?
• Copper characterization: Does the documentation address copper content and complex formation, or only the peptide component?
• Traceability: Do the sample identifier, batch, test date, and laboratory report correspond to the material being evaluated?

A chromatographic purity percentage alone does not answer all of these questions. For more detail, read HPLC vs. LC-MS: Understanding Peptide Purity and Identity Testing and Peptide Certificate of Analysis: How to Read a COA.

How to interpret “GHK-Cu vs. AHK-Cu” responsibly

The comparison is most informative when it identifies a specific question: sequence identity, copper coordination, analytical performance, or a defined experimental endpoint. “Which is better?” has no useful scientific answer without that context. The studies cited here do not provide a basis for ranking the two as personal-use products.

When reading a paper, check whether the investigators tested the free peptide or copper complex, whether the work used an engineered construct, and whether the conclusions stay within the measured endpoints. Publication of a study does not establish equivalence between its test material and an unrelated supplier’s batch.

Research-use-only context

This article provides scientific background and does not recommend either compound for diagnosis, treatment, prevention, or personal use. Peptides Exchange materials are intended strictly for in-vitro laboratory research by qualified professionals, not for human or animal use or consumption.

An RUO statement is not a legal exemption. Under the FDA’s intended-use regulation, relevant evidence can include statements, product design or composition, and circumstances of distribution. FDA warning letters also demonstrate that research disclaimers do not cancel contradictory human-use claims. [7] [8]

Explore additional educational material in the Peptides Exchange Research Library.

Scientific and regulatory sources

1. Pyo HK, et al. (2007). The effect of tripeptide-copper complex on human hair growth in vitro. Archives of Pharmacal Research, 30:834–839. DOI: 10.1007/BF02978833. Laboratory AHK-Cu study; not a human clinical trial.
2. Trapaidze A, et al. (2012). Thermodynamic study of Cu²⁺ binding to DAHK and GHK using isothermal titration calorimetry. Journal of Biological Inorganic Chemistry, 17:37–47. DOI: 10.1007/s00775-011-0824-5.
3. X-ray and solution structures of Cu(II) GHK and Cu(II) DAHK complexes: influence on their redox properties. (2011). Primary structural research.
4. Mehr A, et al. (2020). GHK as a copper-binding tag for macromolecular crystallography. Acta Crystallographica D, 76:1222–1232. DOI: 10.1107/S2059798320013741.
5. An P, et al. (2023). Ultrasensitive and label-free copper-ion detection using GHK-modified asymmetric nanochannels. Analytical Chemistry, 95:13456–13462. DOI: 10.1021/acs.analchem.3c01174.
6. FDA / ICH. Q2(R2) Validation of Analytical Procedures. Final guidance, March 2024.
7. Electronic Code of Federal Regulations. 21 CFR § 201.128: Meaning of intended uses.
8. FDA. Warning letter to Summit Research Peptides. December 10, 2024. Cited for the treatment of RUO disclaimers and intended-use evidence, not as an enforcement finding about GHK-Cu or AHK-Cu.